Physician profile
Deep Adhikari
NPI 1487821989
$3,319.39
in general payments reported to CMS, 2019-2025
23 companies · $903 in 2025
The $903 reported for 2025 was more than what 75% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $126 · 2021: $462 · 2022: $589 · 2023: $490 · 2024: $559 · 2025: $903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,871 · Education: $80.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,871.27 |
| Education | $80.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $598.19 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $372.74 | 2021-2025 | |
| Travere Therapeutics, INC. | $336.29 | 2019-2025 | Filspari |
| Aurinia Pharma U.S., INC. | $273.37 | 2021-2025 | Lupkynis |
| Calliditas Therapeutics US INC. | $173.34 | 2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $163.19 | 2022-2025 | Benlysta, Shingrix, Arexvy |
| Horizon Therapeutics Plc | $157.65 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $157.60 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $150.84 | 2022 | |
| Amgen INC. | $139.96 | 2019-2025 | Tavneos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.89 | 2022-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $94.35 | 2024-2025 | Jynarque |
| Ardelyx, INC. | $92.11 | 2023-2025 | Ibsrela |
| Abbott Laboratories | $87.39 | 2021 | |
| Alexion Pharmaceuticals, INC. | $68.56 | 2021-2023 | Ultomiris |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $63.46 | 2021-2023 | Veltassa, Korsuva |
| Fresenius USA Marketing, INC. | $61.39 | 2021-2024 | Velphoro |
| Ultragenyx Pharmaceutical INC. | $57.62 | 2019-2022 | |
| Novo Nordisk INC | $54.88 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $37.12 | 2024-2025 | Jardiance |
| Genentech USA, INC. | $29.69 | 2025 | Gazyva |
| Akebia Therapeutics INC | $23.05 | 2025 | Vafseo, Auryxia |
| Fresenius USA Manufacturing, INC. | $19.71 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deep Adhikari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.